Table 1

Characteristics of the population

CharacteristicAll patients
(n=623, 100%)
Non-small cell lung cancer
(n=318, 51.0%)
Melanoma
(n=305, 49.0%)
Sex, n (%)
Male
Female
353 (56.7)
270 (43.3)
201 (63.2)
117 (36.8)
152 (49.8)
153 (50.2)
Age (years)
Median range
63 (22–92)63 (34–92)62 (22–91)
Immunotherapy, n (%)
Pembrolizumab
Nivolumab
Nivolumab+ipilimumab
Durvalumab
318 (51.0)
286 (45.9)
10 (1.6)
9 (1.4)
76 (23.9)
233 (73.3)

9 (2.8)
242 (79.3)
53 (17.4)
10 (3.3)
Stage, n (%)
IV
III
II


536 (86.0)
85 (13.6)
2 (0.3)


276 (86.58)
41 (12.9)
1 (0.3)


260 (85.2)
44 (14.4)
1 (0.3)
Metastasis
Bone
Liver
Brain


205 (32.9)
165 (26.5)
183 (29.4)


144 (45.3)
87 (27.4)
87 (27.4)


61 (20.0)
78 (25.6)
96 (31.5)
Prior treatment
Systemic
Radiotherapy
Prior surgery


431 (69.2)
275 (44.1)
335 (53.7)


296 (93.1)
165 (51.9)
98 (30.8)


135 (44.3)
110 (36.1)
237 (77.7)
Outcome
1-year mortality rate
95% CI
Events
0.496
(0.457 to 0.537)
309
0.411
(0.359 to 0.47)
182
0.582
(0.529 to 0.64)
127
5-year mortality rate
95% CI
Events
0.196
(0.165 to 0.233)
477
0.11
(0.0762 to 0.158)
264
0.279
(0.23 to 0.337)
213
Overall survival (months)
Median IQR
11.8
2.9–37.3
8.7
2.1–21.1
19.7
5.6–73.3
Follow-up (months)
Median IQR
10.7
2.7–32.3
7.0
2.0–19.0
18.8
5.3–46.8
Morphometric data
 BMI (kg/m²)
 Mean (±SD)
 (min–max)


24.1 (±4.7)
(13.7–41.4)


23.2 (±4.7)
(13.7–39.9)


25.0 (±4.5)
(16.0–41.4)
 FBM (kg/m²)
 Mean (±SD)
 (min–max)


5.7 (±3.5)
(0.1–21.9)


4.9 (±3.2)
(0.1–18.3)


6.6 (±3.6)
(0.8–21.9)
 SFM (kg/m²)
 Mean (±SD)
 (min–max)


4.8 (±3.0)
(0.1–20.7)


4.1 (±2.7)
(0.1–15.7)


5.5 (±3.1)
(0.8–20.7)
 VFM (kg/m²)
 Mean (±SD)
 (min–max)


0.9 (±0.7)
(0.01–3.4)


0.9 (±0.7)
(0.01–3.4)


1.0 (±0.7)
(0.02–3.3)
 MBM (kg/m²)
 Mean (±SD)
 (min–max)


5.8 (±1.5)
(1.2–14.1)


5.4 (±1.4)
(1.2–9.9)


6.2 (±1.6)
(2.9–14.1)
 LBM (kg/m²)
 Mean (±SD)
 (min–max)


18.3 (±2.8)
(4.9–36.1)


18.2 (±2.6)
(11.7–26.6)


18.4 (±3.0)
(4.9–36.1)
  • BMI, body mass index; FBM, fat body mass; LBM, lean body mass; MBM, muscle body mass; SFM, subcutaneous fat mass; VFM, visceral fat mass.